Where Sutro Biopharma Stands With Analysts
Analysts have provided the following ratings for Sutro Biopharma (NASDAQ:STRO) within the last quarter: Bullish Somewhat Bullish Indifferent…
6 Analysts Have This to Say About Sutro Biopharma
Sutro Biopharma (NASDAQ:STRO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
CaliberCos Inc. (NASDAQ: CWD) shares jumped 65.6% to $9.94 amid post-IPO volatility.
Sutro Biopharma Presents Preclinical Data For Its ROR1 Targeting Antibody Drug Conjugate STRO-003 At The AACR Annual Meeting 2023
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded preclinical data for
Sutro Biopharma Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Sutro Biopharma (NASDAQ:STRO) reported Q4 sales of $8.63 million. Earnings fell to a loss of…
Where Sutro Biopharma Stands With Analysts
Within the last quarter, Sutro Biopharma (NASDAQ:STRO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in today’s session.
Piper Sandler Maintains Overweight on Sutro Biopharma, Raises Price Target to $18
Piper Sandler analyst Edward Tenthoff maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $16 to $18.
Sutro Biopharma Announces Update From STRO-002, Luveltamab Tazevibulin, Phase 1 Dose-Expansion Study And Registrational Plans In Advanced Ovarian Cancer
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6